Media Coverage

To explore what the next year may hold, MLO spoke with 12 laboratory professionals whose roles span bench operations, laboratory quality, enterprise leadership, diagnostics innovation, and health-tech entrepreneurship. Their predictions reflect both optimism and urgency: calls to rebuild the workforce pipeline, integrate multi-site networks, strengthen clinical collaboration, modernize infrastructure, and streamline the process of test result to clinical action. Yuri Fesko, MD, Chief Medical Officer, Quest Diagnostics: "Laboratories across the United States will need to continue being agile and flexible to meet demands from patients, providers, and health systems. That is particularly true in areas like preventive health and wellness, where growth of alternative, consumer-driven models of care will force traditional healthcare providers to be more innovative, dynamic, and user-friendly, allowing patients to interact with this new and growing system closer to home through lab networks like Quest Diagnostics."

Only approximately one-third of US adults diagnosed with hepatitis C virus (HCV) infection received treatment from 2014 to 2021, despite the widespread availability of curative therapies, according to study results published in the Journal of Viral Hepatitis. The US has the fifth highest burden of HCV worldwide. The World Health Organization (WHO) set a goal to eliminate HCV in 2030 by diagnosing at least 90% and treating at least 80% of individuals infected with HCV. Investigators analyzed deidentified data from 2 large commercial laboratories: LabCorp and Quest Diagnostics.

Self-collection for HPV and other infections offers a more convenient, private way to complete recommended screenings—helping reach women who might otherwise delay or skip care. By D. Alagia III, MD, MS, MBA, FACS, FACOG, Quest Diagnostics

Oncologists face a difficult decision after surgically removing a solid tumor. Some patients harbor residual cancer cells, known as minimal residual disease (MRD), and need additional therapy to avoid recurrence, while others are already cured. Determining who falls into each group remains a major challenge in cancer care. “One of the challenges facing ctDNA technologies is, how do we identify ctDNA molecules that are very low abundance in circulation with high accuracy?” said Dan Edelstein, the vice president and general manager of Haystack Oncology at Quest Diagnostics®. Recognizing the need to detect ctDNA reliably, Haystack Oncology developed Haystack MRD®, a next-generation workflow for ultrasensitive residual disease monitoring.

Social media is flooded with ads for at-home blood testing services that promise insights into healthier living, so ABC News' Becky Worley tried one to see what the results really reveal. Becky recieved her blood draw at Quest's patient service center in Oakland, California.

A cancer treatment laboratory in Lewisville made a medical breakthrough that could decrease the risk of the disease returning after a patient has been treated. After somebody has been treated for a cancerous tumor, very small amounts of disease may remain in the body, which traditional tests may miss. Quest Diagnostics, headquartered in Lewisville, has created a new blood test that can identify tiny bits of cancer post-treatment. Currently, Lewisville’s Quest Diagnostics laboratory is the only lab in the country that processes this test for patients and doctors nationwide.

Quest Diagnostics-owned liquid biopsy developer Haystack Oncology is expecting in the next year to bring a new wealth of data supporting the ability of its circulating tumor DNA technology for use in minimal/molecular residual disease (MRD) detection across a variety of indications, especially those where its higher sensitivity may give it a boost over other technologies.

During a talk at the Jefferies Healthcare Services Conference this week, Quest Diagnostics CFO Sam Samad noted developments within several parts of the company's advanced testing business and highlighted blood-based Alzheimer's testing as a particularly strong growth area.

Guardant Health and Quest Diagnostics will collaborate to offer Guardant’s Shield blood-based colorectal cancer test through Quest’s distribution network, the companies said Wednesday. Physicians will be able to order the test through their Quest accounts and electronic health record starting in the first quarter of 2026.

Overall rates of HIV drug resistance declined by nearly 17% between 2018 and 2024, according to a large analysis from Quest Diagnostics published in Open Forum Infectious Diseases. The researchers assessed the prevalence of mutations that confer resistance to nucleoside/nucleotide reverse-transcriptase inhibitors (NRTIs), non-nucleoside reverse-transcriptase inhibitors (NNRTIs), protease inhibitors and integrase inhibitors.